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Currently, several immunotherapies and BACE (Beta Site APP Cleaving Enzyme) inhibitor approaches are
being tested in the clinic for the treatment of Alzheimer’s disease. A crucial mechanism-related safety
concern is the exacerbation of microhemorrhages, which are already present in the majority of Alz-
heimer patients. To investigate potential safety liabilities of long-term BACE inhibitor therapy, we used
aged amyloid precursor protein (APP) transgenic mice (APP23), which robustly develop cerebral amyloid
angiopathy. T2*-weighted magnetic resonance imaging (MRI), a translational method applicable in
preclinical and clinical studies, was used for the detection of microhemorrhages throughout the entire
brain, with subsequent histological validation. Three-dimensional reconstruction based on in vivo MRI
and serial Perls’ stained sections demonstrated a one-to-one matching of the lesions thus allowing for
their histopathological characterization. MRI detected small Perls’ positive areas with a high spatial
resolution. Our data demonstrate that volumetric assessment by noninvasive MRI is well suited to
monitor cerebral microhemorrhages in vivo. Furthermore, 3 months treatment of aged APP23 with the
potent BACE-inhibitor NB-360 did not exacerbate microhemorrhages in contrast to Ab-antibody b1.
These results substantiate the safe use of BACE inhibitors regarding microhemorrhages in long-term
clinical studies for the treatment of Alzheimer’s disease.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cerebral amyloid angiopathy (CAA) is a common feature of
Alzheimer’s disease (AD). At autopsy, approximately 80% of AD
patients have been shown to display CAA (Jellinger, 2002; Vinters,
1987), characterized by extracellular amyloid-beta (Ab) aggregate
accumulation, in particular of the Ab1-40 isoform, in the bloodent, Novartis Institutes for
itzerland. Tel.: þ41 079 543
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Inc. This is an open access article uvessel walls of the brain (Gravina et al., 1995, Haglund et al., 2006).
Furthermore, sporadic CAA (reviewed in Bifﬁ and Greenberg, 2011;
Thal et al., 2008; Vinters, 1987; Viswanathan and Greenberg, 2011;
Yamada, 2000) increases with age, being rarely evident before the
age of 50 years, whereas it is present in more than 50% of people
older than 90 years (Vinters, 1987).
Similar to amyloid plaques, which are found at a low level in
healthy elderly, mild forms of CAA often appear asymptomatic and
seem to be associated with brain Ab deposition in healthy and/or
preclinical AD as well as in AD patients (Park et al., 2013; Yates et al.,
2011, 2014). However, CAA may also lead to severe vascular pa-
thologies including degeneration of smooth muscle cells and
disruption of the blood-brain barrier (Itoh et al., 1993; Kawai et al.,
1993; Vinters, 1987). CAA is a risk factor for cerebral hemorrhages
ranging from silent microbleeds to stroke (Zhang-Nunes et al.,
2006). Although about 80% of subjects with AD show CAA atnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hemorrhage (Greenberg et al., 2004). However, new reports argue
that microbleeds seem to be quite common in AD and prodromal
AD (Brundel et al., 2012; Kantarci et al., 2013). In vivo detection of
such microhemorrhages in the human brain by imaging (reviewed
by Johnson et al., 2012) gains increasing importance as these lesions
potentially indicate a risk of hemorrhagic stroke or contribute to
progressive cognitive dysfunction (O’Brien et al., 2003; van der
Flier, 2012), although the role of CAA in the pathogenesis of AD is
debated (Heringa et al., 2014; Nicoll et al., 2004; reviewed by
van der Flier, 2012).
Active or passive Ab immunotherapy has proven to be an
effective means to reduce the amyloid plaque load in human or
mouse brain (reviewed in Klafki et al., 2006). However, vascular Ab
transiently increased after amyloid plaque reduction during
AN1792 (beta-amyloid [Ab]1-42) immunotherapy, which suggests
deposition of parenchymal Ab in the vasculature (Boche et al.,
2008). No damage of vascular smooth muscle cells but increased
splitting of the vessel wall was observed in the leptomeningeal
vessels of immunized subjects (Sakai et al., 2014). Treatment with
bapineuzumab, an Ab antibody, appeared to increase the risk of
microhemorrhages (ARIA-H), edema (ARIA-E), and CAA (Arrighi
et al., 2016; Roher et al., 2013; Salloway et al., 2009).
Different amyloid precursor protein (APP) transgenic mouse
lines show a varying degree of CAA (reviewed by Klohs et al., 2014).
APP23mice develop relatively strong CAA (Calhoun et al., 1999; Kuo
et al., 2001) that may be associated with microhemorrhages
(Winkler et al., 2001). In some studies using APP transgenic mice
passive immunization led to an increase in CAA and micro-
hemorrhages (Beckmann et al., 2011; Luo et al., 2012; Meyer-
Luehmann et al., 2011; Pfeifer et al., 2002; Racke et al., 2005;
Wilcock et al., 2004). However, other investigations in APP mice
showed no such effects (Asuni et al., 2006; Levites et al., 2006).
Taken together, clinical data and ﬁndings from animal studies
concerning Ab immunotherapy raised an important mechanism-
related safety concern possibly relevant to all Ab-lowering treat-
ments (Sperling et al., 2011).
It is currently unknown if beta site APP cleaving enzyme (BACE-
1) (b-secretase) inhibitor treatment may lead to cerebral micro-
hemorrhages, and an assessment of the risk in preclinical studies is
therefore urgently needed. In this study, we chronically treated
aged APP23 mice with the BACE inhibitor, NB-360 (Neumann et al.,
2015). The b1 antibody (Paganetti et al., 1996) was used here as
positive control, as previous studies revealed that treatment with
the b1 antibody increased microvascular lesions in the brains of
APP23 mice (Beckmann et al., 2011; Pfeifer et al., 2002). We show
that 3-dimensional (3D) T2*-weighted magnetic resonance imag-
ing (MRI) during the treatment period provided a sensitive
detection of microhemorrhages, comparable with postmortem
histological evaluation. Both methods did not show any signs of
exacerbation of microhemorrhages in APP23 mice upon BACE in-
hibitor treatment. In contrast, increased microhemorrhage for-
mation was found in the brains of APP23 mice treated with the b1
antibody.
2. Materials and methods
2.1. Ethics statement
Experiments were carried out in accordance with the guidelines
of the Swiss Federal and Cantonal veterinary ofﬁces for care and use
of laboratory animals. Studies described in this report were
approved by the Swiss Cantonal Veterinary Authority of Basel City,
Switzerland and performed according to animal license number BS-
2063. Compound dosing as well as data acquisition and analyseswere performed by investigators blinded to experimental treat-
ment groups.
2.2. In vivo experiments: animals, compound formulation and
dosing
For these studies n ¼ 74 female APP23 transgenic mice (B6.D2-
Tg (Thy1App) 23/1Sdz) and n ¼ 20 female wild-type littermates
(Novartis internal colonies, Basel, Switzerland) were used. APP23
mice express human APP751 with Swedish mutations, under the
control of the murine Thy-1 promotor (Sturchler-Pierrat et al.,
1997). Plaque deposition starts at approximately 6e8 months of
age in APP23 mice. Female mice were used as they produce more
Ab40 and Ab42 than males and thus show more robust and read
amyloid pathology in the brain (Eisele et al., 2014; Sturchler-Pierrat
and Staufenbiel, 2000).
Animals for studying spontaneous lesion development in aging
APP23 mice (Fig. 1): 14 female APP23 mice were examined longi-
tudinally by MRI from age 13.7 to 20.5 months.
BACE inhibitor NB-360/b1 antibody study (Figs. 2e5): 20 female
APP23 per treatment group and 20 wild-type littermates were
treated for 3 months from the age of 17.5 until 20.5 months. Ani-
mals were randomly grouped according to the number of lesions
detected in theMRI before the start of the treatment. Average lesion
numbers per group: 6 1 (means standard error of mean [SEM]).
Mice were dosed per os chronically for 3 months with either the
BACE inhibitor NB-360 (30 mmol/kg; Novartis Pharma AG, Basel,
Switzerland), or vehicle. Crystalline NB-360 was formulated as a
suspension. Vehicle (0.1% Tween80 in 0.5% methylcellulose in wa-
ter) or compound were given in a volume of 10 mL/kg once daily (in
the morning). Further animals were dosed intraperitoneally weekly
for 3 months with either b1mouse monoclonal IgG2a antibody that
recognizes amino acids 3e6 of human Ab (Paganetti et al., 1996) or
mIgG control antibody (anti-Cyclosporin-A; ﬁrst dose 0.4 mg/
mouse, then 0.5 mg/kg).
Mice were single-housed and maintained under standard con-
ditions in temperature and humidity controlled rooms under a 12/
12 light/dark schedule, with lights on at 05:00 AM. Cage bedding
consisted of sawdust and a red Perspex house (Nalgene, Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Nesting materials (Nestlet,
Ancare, Bellmore, NY, USA) and a wooden gnawing-block were
supplied in each cage. Tap water and standard laboratory rodent
food were available ad libitum.
2.3. Magnetic resonance imaging
Three-dimensional T2*-weighted images covering the whole
brain were acquired at 7 T using a Biospec 70/30 spectrometer
(Bruker Medical Systems, Ettlingen, Germany) equipped with an
actively shielded gradient system. The operational software of the
scanner was Paravision PV5.1 (Bruker). Images were obtained using
a 3D gradient-echo sequence with the following imaging parame-
ters: repetition time 24.3 ms, echo time 10 ms, matrix 256  128 
192, ﬁeld-of-view 1.5  1.5  2.4 cm3. Total acquisition time for an
image having a voxel size of 59  118  125 mm3 was 10 minutes.
Shimming (homogenization of the magnetic ﬁeld) was performed
for every animal and imaging session before acquiring a 3D image.
During MRI acquisitions, mice were anaesthetized with isoﬂurane
(Abbott, Baar, Switzerland) administered via a face mask and placed
in a cradle made of Plexiglas. The head was ﬁxed by using a tooth
holder. Body temperature was maintained at 37 1 C via warming
blankets or integrated water hoses in animal beds. Respiration and
body temperature were monitored throughout the acquisition. The
duration of an imaging session was about 15 minutes, including
positioning of the mouse.
Fig. 1. MRI detection and distribution of brain lesions in aged APP23 mice. (A) Segmentation of lesions (red arrows) detected in the brains of APP23 mice. Two images extracted from
a 3D data set are shown on the left side. On the right side, the corresponding segmented lesions are displayed. The total volume of lesions was determined by adding the segmented
areas on the individual images, multiplied by the slice thickness. The red lines delimitate the regions in which lesions were segmented. (B) Number of lesions (means  SEM, n ¼ 14
mice at the beginning of the study) in the brains of APP23 mice, from age 13.7 to 20.5 months. (C) MR images were extracted from a 3D data and are sequentially displayed from
caudal to rostral (from left to right, from top to bottom). Lesions detected by MRI (red arrows) were encountered predominantly in rostral areas of the brain. (D) Volumes of lesions
shown in B (means  SEM, n ¼ 14 mice at the beginning of the study) in the brains of APP23 mice, from age 13.7 to 20.5 months. Abbreviations: MRI, magnetic resonance imaging;
SEM, standard error of mean.
N. Beckmann et al. / Neurobiology of Aging 45 (2016) 50e6052Sites in the cortex and thalamus presenting signal attenuation
with a minimum diameter of 150 mm were analyzed (counts, vol-
umes) throughout thewhole brain. To ensure that the same sitewas
not counted multiple times, its presence was carefully controlled
over several consecutive slices from the 3D data set. The lesion
volume was determined using specialized software (ImgTool),
developed in-house. A detailed description of the software can be
found in (Babin et al., 2012; Egger et al., 2013). The software has
been validated and is in routine use since 2001. For each slice of the
3D data set, the areas of the signal attenuation sites within an
external border were determined by applying an image segmen-
tation algorithm. The total volume of the lesions was obtained by
adding the areas assessed on the individual slices and multiplying
by the slice thickness (125 mm).
Statistical analyses of lesion volumes comprised analysis of
variance (ANOVA) with random effects (SYSTAT 12, Systat Software,
Inc, San Jose, CA, USA) to take into account the longitudinal struc-
ture of the data. ManneWhitney analyses (SYSTAT 12) wereperformed on lesion numbers. A p < 0.05 was considered statisti-
cally signiﬁcant.2.4. Postmortem analyses
At the end of the study, animals were euthanized. The brains
were removed and ﬁxed for histology, or the forebrain was frozen
and used for assessments of Ab levels.2.5. Ab measurement
2.5.1. Brain homogenization
Frozen mouse forebrains were weighed and homogenized in 9
volumes (w/v) of ice-cold TBS-Complete (20 mM Tris-HCl pH 7.4,
137 mM NaCl, 1 Complete [Protease Inhibitor Cocktail Tablets:
1,836,145, Roche Diagnostics GmbH, Penzberg, Germany]) by son-
ication (90% duty cycle, output control 5, 40e55 pulses, [Soniﬁer
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Fig. 2. Exposure of NB-360 in the blood and brain and pharmacodynamics effect on amyloid-b (Ab40 and Ab42) in the forebrain. (A) NB-360 levels in plasma and brain at 4 hour
(n ¼ 6) and 24 hour (n ¼ 5) after last dosing (means  SEM). (B) Ab40 and Ab42 determination in forebrain of treated animals at the end of the study (means  SEM); baseline:
n ¼ 20, b1 antibody: n ¼ 17, control: n ¼ 15, NB-360: n ¼ 12. The levels of signiﬁcance ***p < 0.001 refer to 1-way ANOVA with HolmeSidak’s multiple comparison to the control
group. Abbreviations: ANOVA, analysis of variance; MRI, magnetic resonance imaging; ns, not signiﬁcant; SEM, standard error of mean.
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mL aliquots were prepared for analysis and stored at 80 C.
2.5.2. Extraction and determination of Ab40 and Ab42 in mouse
forebrain
Ab40 and Ab42 were determined as previously described
(Neumann et al., 2015) using the MSD Ab40 and Ab42 Ultra-
sensitive Kits (Meso Scale Diagnostics, Gaithersburg, MD, USA).
The assays were performed according to the manufacturer’s in-
structions and the sample preparations described as follows.
TritonX-100 (TX-100) soluble Ab was extracted from the forebrain
with 1% TX-100 using a 50 mL aliquot of each 1:10 forebrain ho-
mogenate, mixed with 50 mL 2% TX-100 in TBS complete (20 mM
Tris-HCl pH 7.4, 137 mM NaCl, 1 Complete [Protease Inhibitor
Cocktail Tablets: 1,836,145, Roche Diagnostics GmbH, Penzberg
Germany]) to reach a ﬁnal concentration of 1% TX-100 and a 1:20
forebrain dilution. Samples were incubated for 15 minutes on ice
and vortexed every 5 minutes. Afterward, they were centrifuged
(100,000  g, 4 C, 15 minutes, Ultra-centrifuge) and 50 mL of the
clear supernatants were transferred to fresh tubes. For the Ab40
assay, supernatants were further diluted 1:10 in 3% Blocker A so-
lution (from kit) to a ﬁnal forebrain dilution of 1:200 and applied
to the plate. Supernatants were not diluted for the determination
of Ab42. For the extraction of insoluble amyloid peptides, 50 mL
forebrain homogenate was mixed with 117 mL of 100% formic acid
and stored on ice for 15 minutes with vortexing. Samples were
neutralized with 950 mL 1 M Tris base, containing complete pro-
tease inhibitor cocktail (Roche, Basle, Switzerland) and stored
overnight at room temperature. The supernatant after 15 minutes
centrifugation at 14000 rpm was used for analysis. Nontransgenicmouse forebrain homogenates spiked with synthetic Ab were used
for preparation of the standard curves and treated identically to
samples. For all samples and standards, 25 mL were applied per
well. The mean values from the duplicate wells were used for
calculations. The relative units for samples and standards were
imported into SOFTmax PRO 4.0 (Molecular Devices, Sunnyvale,
CA, USA) for calculation of standard curves and quantiﬁcation of
samples.
2.6. Determination of NB-360
The determination of NB-360 in mouse plasma was
performed after protein precipitation followed by liquid
chromatographyemass spectrometry/mass spectrometry using
electrospray ionization in positive mode. Brain samples were ho-
mogenized with 4 volume equivalent of acetonitrile and/or water
(1/1), and processed like the plasma samples.
2.6.1. Plasma analyses
To an aliquot of 20 mL of plasma sample, 40 mL of acetonitrile
containing an internal standardwere added. After vortexmixing for
a few seconds, samples were centrifuged for 10 minutes at 50,000 g
and at 8 C. An aliquot of 40 mL of supernatant was transferred to an
autosampler vial and 40 mL of water were added, before analysis.
2.6.2. Brain analyses
2.6.2.1. Homogenization. Brain samples were weighed and ho-
mogenized with 4 volume equivalents of a mixture of acetontrile
and/or water (1/1, v/v) in appropriate Lysing Matrix tubes with a
homogenizer at 5000 oscillations for 30 seconds. Afterward,
Fig. 3. MRI of APP23 female mice treated with either b1 antibody, BACE inhibitor NB-360, or control IgG2 antibody for 3 months. (A) MRI images of a mouse treated with the control
antibody (left) and with the b1 antibody (right) from different brain areas at baseline and after 1, 2, and 3 months of treatment. Three slices at approximately the same anatomical
location and extracted from 3D data sets are shown per time point. Red arrows point to a lesion that persists, green arrows point to a lesion that disappears. (B) Mean number of
lesions in the whole brain (means  SEM, n ¼ 20 mice per group at the beginning of the study). The levels of signiﬁcance *0.01 < p < 0.05, **0.001 < p < 0.1, and ***p < 0.001 refer to
ManneWhitney comparisons with respect to baseline values. (C) Lesion volume (means  SEM). The levels of signiﬁcance *0.01 < p < 0.05, **0.001 < p< 0.1, and ***p < 0.001 refer to
ANOVA with random effects comparisons to baseline values, within each group. The levels of signiﬁcance #0.01 < p < 0.05, ##0.001 < p < 0.1, and ###p < 0.001 refer to ANOVA
with random effects comparisons as indicated. (D) Differential, baseline-subtracted lesion volume (means  SEM). The levels of signiﬁcance *0.01 < p < 0.05, **0.001 < p < 0.1, and
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Fig. 4. Histopathological analyses of mice treated with either b1 antibody, BACE inhibitor NB-360 or control IgG2 antibody for 3 months. (A) Histological sections stained with Perls’
Prussian blue and hematoxylin and/or eosin indicate the presence of hemosiderin (white arrow). The black asterisks depict parenchymal amyloid plaques. (B) Grading by a
pathologist of the Perls’ Prussian blue stained sections (n ¼ 3 per mouse). (C) Histological section depicting clusters of Perls’ Prussian blue staining obtained by ASTORIA analyses. (D)
Quantiﬁcation of the cluster numbers of Perls’ Prussian blue stained sections (mean  SEM). Signiﬁcance levels p refer to 1-way ANOVA Holm-Sidak’s multiple comparisons to the b1
antibodyetreated group (**0.001 < p < 0.01). b1 antibody: n ¼ 15, NB-360: n ¼ 10, control: n ¼ 13. Abbreviations: ANOVA, analysis of variance; MRI, magnetic resonance imaging;
SEM, standard error of mean.
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N. Beckmann et al. / Neurobiology of Aging 45 (2016) 50e60 55homogenates were centrifuged for 10 minutes at 16,000 g, and
supernatants were transferred to assay tubes.
2.6.2.2. Preparation. To an aliquot of 20 mL of homogenate sample,
40 mL of acetonitrile containing an internal standard were added.
After vortex mixing for a few seconds, samples were centrifuged for
10 minutes at 50,000 g and at 8 C. An aliquot of 40 mL of super-
natants was transferred to an autosampler vial and 40 mL of water
were added, before analysis.
2.7. Histology and image analysis
2.7.1. Brain analyses: Perls’ Prussian blue reaction for hemosiderin
detection
The Perls’ Prussian blue reaction was performed at 37 C on
formalin-ﬁxed parafﬁn-embedded tissue sections of approximately
5 mm thickness using the Iron Staining Kit (Ventana/Roche, Tucson,
AZ, USA) on theVENTANABenchMark Special Stains automated slide
stainer (Ventana/Roche). Formalin-ﬁxed parafﬁn-embedded***p < 0.001 refer to ANOVAwith random effects comparisons to baseline values, within eac
refer to ANOVA with random effects comparisons as indicated. (E) Corresponding normalize
levels of signiﬁcance *0.01 < p < 0.05 and ***p < 0.001 refer to ANOVA with random effects
of signiﬁcance #0.01 < p < 0.05 and ##0.001 < p < 0.01 refer to ANOVA with random eff
resonance imaging; SEM, standard error of mean.sections were deparafﬁnized and rehydrated followed by applica-
tion of 200 mL Iron Reagent A (Ventana/Roche) for 4 minutes and
subsequent applicationof 200 mL IronReagent B (Ventana/Roche) for
another 4 minutes. Finally, 200 mL Iron NuclearFast Red (NFR; Ven-
tana/Roche) was applied on each slide. After counterstaining with
NFR (Ventana/Roche), the slides were dehydrated and mounted
using Pertex (Biosystems Switzerland, Nunningen, Switzerland).
The distribution, size, and staining intensity of hemosiderin
depositions were assessed by light microscopy with a special focus
on their associationwith blood vessel and Ab plaques brain sections
located at the level of optic chiasm, anteriormidbrain, and posterior
colliculus. The grading criteria for hemosiderin deposition in the
brain were based on the following scale for reporting pathological
changes (Zago et al., 2013): minimal (grade 1), very small hemo-
siderin deposits  association with blood vessels and/or beta-
amyloid plaque; mild (grade 2), small hemosiderin foci associated
with blood vessels and/or beta-amyloid plaques; moderate (grade
3), moderate-sized hemosiderin foci associated with blood vessels
and/or plaques.h group. The levels of signiﬁcance #0.01 < p < 0.05, ##0.001 < p < 0.1, and ###p < 0.001
d lesion volume increase factor detected by MRI in the whole brain (mean  SEM). The
comparisons to factors determined at 18.5 months of age, within each group. The levels
ects analyses as indicated. Abbreviations: ANOVA, analysis of variance; MRI, magnetic
Fig. 5. Three-dimensional reconstruction of MRI and histological sections. (A) Serial Perls’ Prussian blue stained sections were aligned, rotated, and shifted for 3D reconstruction.
(B) Lesion visualized by Perls’ Prussian blue was detected, and a hull around the detected segments was constructed. Orange arrow: major lesion; blue arrows: minor lesions. (C)
Three-dimensional reconstruction of the MRI images. Pale yellow depicts the area covered by the histological sections, red the Perls’ Prussian blue staining. (D) Three-dimensional
reconstruction of the MRI images as in (C), but the brain area was rendered transparent to visualize the lesions inside it shown in light red, whereas the portion of lesion on the brain
surface is marked in dark red. (E) Rendering of reconstructed lesions for MRI (left) and histology (right). Abbreviations: MRI, magnetic resonance imaging; SEM, standard error of
mean.
N. Beckmann et al. / Neurobiology of Aging 45 (2016) 50e6056Statistical analyses of the grading of lesions comprised 1-way
ANOVA with Dunn’s multiple comparison tests (GraphPad Prism
V6.04, GraphPad Software, Inc, La Jolla, CA, USA).
2.7.2. Image analysis
For the quantitative microhemorrhage evaluation based on im-
age analysis, a proprietary image analysis platform (ASTORIA,
Automated Stored Image Analysis) was developed in-house
(Novartis Preclinical Safety, Basel, Switzerland) based on MS Vi-
sual Studio 2010 and many functions from Matrox MIL V9 libraries
(Matrox Inc, Quebec, Canada).
For the hemosiderin deposit analysis, the following sequence of
steps was performed: (1) Slide scanning with a Hamamatsu
Nanozoomer (20; Hamamatsu Photonics, Solothurn,
Switzerland); (2) automated detection of brain sections (Fast Red
staining) on the scans to generate region of interest and creation
and export of tif image tiles within the region of interest using the
proprietary ImageScope (Aperio Inc, Vista, CA, USA) plug-in; and
(3) image batch processing with the ASTORIA image analysis
platform for detection of a valid brain area (Fast Red staining),
various thresholding techniques and morphological trans-
formations for segmentation of bluish (Perls’ positive) objects,
rejection of objects too close to the brain section’s periphery to
exclude bleeding due to mechanic rupture of tissue, rejection of
staining artifacts, feature based object classiﬁcation, and determi-
nation of clusters.The image analysis for hemosiderin deposit detection and
measurement comprised the following steps: (1) extract red, green,
and blue channels from stored tif images as gray images; (2) get a
valid sample area through adding difference red-green channel to
difference red-blue channel image, binarization by thresholding.
Add sufﬁciently high signal in blue-red difference to include heavily
blue stained objects; (3) perform morphological closing, opening,
and ﬁlling of holes (Matrox Imaging Library, Rauscher, Olching,
Germany); (4) remove sample edges from a valid range by sub-
tracting dilated background; (5) segment bluish hemosiderin de-
posits by starting from blue:red ratio and thresholding to obtain
“maximum” markers, then reconstruct from “minimal” markers
(seeds) that fulﬁlled a minimum blue:red ratio requirement
(Matrox Imaging Library); (6) add objects from thresholded HSI
(Hue, Saturation, Intensity) image; (7) restrict the maximum in-
tensity in the red channel to exclude heavily pink-stained objects;
(8) get minimal seed markers through binarization on the blue-red
image and size ﬁltering; then reconstruct to obtain sets of all valid
objects. Restrict to a valid sample range (see [3] previously
mentioned); (9) determine and remove too bright regions (based
on HSI); (10) remove objects that did not extend sufﬁciently far
from the image frame; (11) individually classify objects based on
morphometric and densitometric features: an “artifact” class was
characterized by morphometric object features (size, shape) or
amount of “darkness” in the blue channel, i.e. too dark (black dust)
features. Objects falling in this class were disregarded from the
N. Beckmann et al. / Neurobiology of Aging 45 (2016) 50e60 57analysis. Various combinations of gray features in the red, green,
and blue channels with morphometric features (size, shape) were
used to determine valid hemosiderin deposits and to exclude arti-
facts. Each of these ﬁlter criteria had to be determined for a valid
object; (12) deﬁne clusters by 100 dilations and 70 erosions of the
detected objects (generate large images by including neighbor
tiles). A valid cluster consisted of at least 2 valid objects that had
passed step (10); and (13) store morphometric and densitometric
features for each hemosiderin object for statistical analysis.
Theparametersmeasured foreach samplewere (1) Perls’positive
ratio (total blue area vs. total brain section area), (2) number of in-
dividual hemosiderin deposits (blue objects), and (3) number of
clusters (2 depositswithin limited distance). Assessment using the
average of 3 sections for each animal was considered to be repre-
sentative and in line with the pathologist’s assessment for grading.
Statistical analyses comprised 1-way ANOVAwith HolmeSidak’s
multiple comparison tests (GraphPad Prism V6.04).2.8. Three-dimensional reconstruction from histological serial
sections and MRI images
Three-dimensional reconstructions were performed from serial
histological sections and coregisteration of the reconstructed vol-
ume to the MRI data using a stereotactic Allen mouse brain atlas
(http://mouse.brain-map.org/static/atlas, Allen Institute for Brain
Science, Seattle, WA, USA) for positional reference. Image analysis
was conducted on the Perls’ stained histological sections and the
MRI data with Deﬁniens Developer XD software (Developer XD 2.0,
Deﬁniens, Munich, Germany), using speciﬁcally developed image
analysis algorithms.2.8.1. Histology sample preparation
The anterior part of half a brain was cut into serial coronal
sections of approximately 5 mm thickness, using a microtomewith a
cool cut head. The region taken corresponded to stereotactic co-
ordinates in the mouse brain atlas (Franklin and Paxinos, 2008)
plates 15e40 (approximately interaural position 5.74e3.74). Two
consecutive sections were placed on each glass slide. Assessment of
hemosiderin deposition was performed by the Perls’ Prussian blue
reaction as described above.2.8.2. Digital whole-slide scanning
Glass slides were scanned for subsequent image analysis using a
Philips slide scanner (Philips Ultra-Fast Scanner, version 1.6 & Image
Management System, version 2.2, Philips Digital Pathology, Best,
The Netherlands). A 40 objective was used for scanning, resulting
in a pixel size of 0.25 mm in x and y directions.2.8.3. Three-dimensional reconstruction from serial histological
sections
Tissue sections were detected in the digital slide scans and
aligned using linear afﬁne transformation, matching the center
of gravity and the direction of the main axis. Sections lost (37
lost sections [8%] due to technical issues) in the preparation
process were replaced by repeating previous sections. Perls’
staining was detected using color deconvolution and subsequent
thresholding.2.8.4. Three-dimensional reconstruction from MRI data
MRI data were exported into tif ﬁle format, resampling the non-
uniform x and y image matrix (pixel size x: 59 mm; y: 117 mm) toresult in a square image matrix. The resampled images were then
analyzed using a speciﬁcally designed algorithm to delineate the
area of the brain and the areas of signal attenuation representing
microhemorrhages. Three-dimensional rendering of the borders of
detected areas was then performed.2.8.5. Coregistration of MRI and 3D reconstructed histology data
To coregister the MRI volume and the volume sampled from
histological serial sections, both data sets have been registered
manually to the Allen stereotactic mouse brain atlas, identifying
morphological brain features in the MRI and histological data and
ﬁnding the closest corresponding z location in the atlas. Thus, the
atlas coordinate system has been established as the common co-
ordinate system for both data sets. To aid the visualization of the
coregistered data set, the MRI data have been resampled to
approximately match the pixel resolution imposed by the histo-
logical sections. Frame interpolation software (slowmoVideo,
http://slowmovideo.granjow.net/, Simon A. Eugster, bachelor
thesis ETH Zurich, Zurich, Switzerland) has been used to add
frames to the MRI data to change the z-slice distance from 125 mm
to approximately 5 mm. Bicubic interpolation has been used for x
and y coordinates to match the resolution of the digital slide scan
data of the histological slides.3. Results
3.1. Quantiﬁcation of microhemorrhages in aged APP23 mice using
T2*-weighted MRI
Aged APP23 animals display microhemorrhages in different
parts of the brain (Winkler et al., 2001). These events can be visu-
alized by T2*-weighted MRI as sites of attenuated signals (Fig. 1A)
and their number quantiﬁed (Beckmann et al., 2011). In agreement,
MRI-detectable microhemorrhages in the present study started to
appear at the age between 15 and 17 months and gradually
increased in number (Fig. 1B). Most of the lesions were detected in
the rostral part of the brain and appeared isolated and randomly
distributed (Fig. 1C, red arrows). The caudal part was devoid of le-
sions at ages up to 20.5 months in APP23 mice (Fig. 1C). To obtain a
better measure of their severity, we determined the total lesion
volume per mouse brain. A substantial increase was detected dur-
ing the aging process with an average lesion volume of 0.04 
0.07 mL (means  SEM, n ¼ 14 mice) at 17.5 and 0.21  0.04 mL
(means  SEM, n ¼ 12 mice) at 20.5 months of age (Fig. 1D). As
expected from histological analyses of microhemorrhage (Winkler
et al., 2001), the total lesion volume determined for each mouse
brain varied considerably. It ranged from 0.01 to 0.13 mL at
17.5 months of age and from 0.13 to 0.42 mL at 20.5 months of age.
Taken together aged APP23 displayed sparse and random micro-
hemorrhages in cortical and thalamic areas of the rostral brain. The
number and volume of these lesions could be quantiﬁed using
T2*-weighted MRI which demonstrated an increase with age.3.2. BACE inhibitor treatment did not aggravate microhemorrhage
in aged APP23 mice
We next treated aged APP23 animals for 3 months (from 17.5 to
20.5 months of age) with the very potent and brain-penetrable
BACE inhibitor NB-360 at a high therapeutic dose of 30 mmol/kg/
day (Neumann et al., 2015). As a positive control, we used the b1
antibody (Paganetti et al., 1996) which is known to induce micro-
hemorrhages in APP23 (Pfeifer et al., 2002). Plasma and brain
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[Neumann et al., 2015]). Bodyweight of APP23 animals was reduced
by approximately 25% compared to wild-type mice but did not
differ between the different treatment groups (data not shown).
NB-360 treatment of aged APP23 resulted in a signiﬁcant lowering
of Ab40 and Ab42 in the forebrain comparedwith vehicle treatment
(Fig. 2B). No signiﬁcant difference from baseline was found after a
3-month BACE inhibitor treatment (Fig. 2B). Mice immunized with
the b1 antibody showed a signiﬁcant reduction of Ab42 but not
Ab40 in the forebrain (Fig. 2B) as described earlier (Pfeifer et al.,
2002). Thus, BACE-inhibitor treatment and passive immunization
were highly effective in lowering forebrain Ab in aged APP23 mice.
Longitudinal T2*-weighted MRI measurements (Fig. 3A) of
vehicle-treated animals (nonrelevant antibody) showed an age-
dependent increase in lesion number and volume (Fig. 3B and C).
Changes of both parameters in NB-360 treated mice were similar
and not signiﬁcantly different from the vehicle-treated APP23
(Fig. 3B and C). In contrast, a signiﬁcantly greater increase in lesion
volume (absolute and differential, baseline-subtracted volume) but
not lesion number was found in b1 immunized compared with
vehicle-treated animals (Fig. 3BeD). In a few of b1 immunized mice
very large lesions (>1 mL) were detected, which were absent in the
other treatment groups (Fig. 3A). Furthermore, the relative lesion
volume increase for each individual animal, i.e. the total lesion
volume at study end divided by the corresponding volume at
baseline was calculated and resulted in similar changes (Fig. 3E).
One animal in the b1 group that had no lesion at the start of the
study was excluded from this analysis. In summary, BACE-inhibitor
treatment for 3 months did not aggravate MRI-assessed micro-
hemorrhage development in aged APP23 mice in contrast to the b1
antibody serving as positive control.
After 3 months of treatment, APP23 animals were killed and
their brains subjected to histological analyses. Perls’ staining was
performed on 3 different brain sections, and hemosiderin deposits
were graded (seeMaterial andMethods) by a pathologist blinded to
treatment groups (Fig. 4A and B). Hemosiderin staining was
observed in the APP23 mice irrespective of the treatment group.
Only minimal-to-mild hemosiderin deposition was found in BACE-
inhibitor NB-360 treated (39% of animals) and vehicle-treated (27%
of animals) mice. In contrast, mild-to-moderate hemosiderin
deposition was detected after b1 treatment (44% of animals). Thus,
BACE-inhibitor NB-360 did not increase the severity of the hemo-
siderin deposits (Fig. 4B). In b1-antibody immunized APP23 mice
only a slight, nonsigniﬁcant increase in the severity of hemosiderin
deposition was observed (Fig. 4B). Concerning the appearance and
distribution of the hemosiderin deposits no differences were noted
between NB-360, b1-antibody, and vehicle-treated animals.
A more reﬁned quantiﬁcation of microhemorrhages was per-
formed by image analysis using ASTORIA (Fig. 4C and D). The
stained sections were scanned and analyzed for Perls’ stained area
(stained area normalized to the total area), deposits (individual
hemosiderin deposits [blue objects]), and clusters (2 deposits
within limited distance). The Perls’ stained area (means 
SEM,107) was similar in NB-360 (98.5 40.9, n¼ 10) and vehicle-
(101.5 21.2, n¼ 13) treatedmice. The b1 group (255.9 127.4, n¼
15) was greater than the vehicle group, but the difference was not
statistically signiﬁcant (p¼ 0.382, NB-360 vs. b1-antibody group, 1-
way ANOVA HolmeSidak’s multiple comparison test). Similarly, the
numbers of Perls’ positive deposits (means  SEM) were compa-
rable for the NB-360 (4.2  0.7, n ¼ 10) and vehicle (7.2  1.5, n ¼
15) group and higher in the b1-antibody group (8.6  1.9, n ¼ 15)
but without reaching statistical signiﬁcance (p ¼ 0.139, NB-360, 1-
way ANOVA HolmeSidak’s multiple comparison test). Finally,
cluster analysis (Fig. 4C) revealed lower cluster numbers in BACE-
inhibitor NB-360 and vehicle-treated APP23 mice compared withmice immunized with the b1 antibody (Fig. 4D). Taken together, the
quantitative assessment of hemosiderin deposition using digital
image analysis on only a limited number of brain sections
conﬁrmed the MRI-assessed increase in microhemorrhages after b1
immunotherapy but not NB-360 treatment. Furthermore, Perls’
positive clusters and deposits correlated signiﬁcantly with the MRI
lesion volume (Pearson r¼þ0.549, p< 0.0004, and r¼þ0.463, p<
0.0039, respectively) but not with the MRI lesion numbers (Pearson
r ¼ þ252, p ¼ 0.132 and r ¼ þ0.271, p ¼ 0.105, respectively).
3.3. Three-dimensional reconstruction from histological serial
sections and MRI images reveals sufﬁcient sensitivity of in vivo
volumetric microhemorrhage assessment by MRI
To evaluate the sensitivity of T2*-weighted MRI measurements
in detecting microhemorrhages in the APP23 mouse brain, we
comparedMRI and histological sections from one animal. First, a 3D
reconstruction of histological sections needed to be established. For
this, sequential coronal sections (468 sections) from the anterior
part of a brain half were collected, then stained with Perls’ and
scanned. For an aligned stack of images, the scanned serial sections
were rotated and shifted. Finally, microhemorrhages, which are
Perls’ positive, were assessed by image analyses, and a hull was
added around detected segments (Fig. 5A). In this stack of images of
this animal 4 hemosiderin clusters could be observed (Fig. 5B).
Besides the very big microhemorrhage (Fig. 5B, brown arrow), 3
smaller hemosiderin positive clusters were visible (Fig. 5B, blue
arrows).
To compare the stack of histological sections to the T2*-weighted
MRI measurements, MRI images (125 mm slice distance) from the
same animal were 3D reconstructed (Fig. 5C, dark yellow). The
brain area for which sections were histologically processed is
marked in light yellow color (Fig. 5C), and the large lesion detected
by MRI is shown in red (Fig. 5C). This big lesion was located on the
surface of the brain, whereas the other smaller lesions were found
inside the brain, which can be visualized by rendering the brain
transparent (Fig. 5D). Similar to histology, 4 lesions in this brain
area could be detected by T2*-weighted MRI. To demonstrate that
lesions detected by Perls’staining and MRI were identical, MRI
in vivo imaging and histological sections were combined by cor-
egistration and rendering both data sets. The rendering of the
reconstructed lesions are shown in Fig. 5E, for T2*-weighted MRI
and histology with the same color code. The corresponding lesions,
shownwith different colors, reveal a one-to-one match of lesions of
Perls’ stained-sections and in vivoT2*-weightedMRImeasurements
(Fig. 5E). Thus, MRI and histopathology correlated very well and
MRI detected small Perls’ positive clusters with sufﬁcient extent
along the z-axis. Taken together, volumetric assessment by T2*-
weightedMRI is very sensitive and detects small lesions with a high
spatial resolution and thus supports in vivo monitoring of cerebral
microhemorrhages in animal studies.
4. Discussion
Immunotherapies against Ab have shown an increased inci-
dence of microhemorrhages (Arrighi et al., 2016; Bayer et al., 2005;
Gilman et al., 2005; Orgogozo et al., 2003; Roher et al., 2013;
Salloway et al., 2009). This raises more general safety concerns
regarding all therapeutic approaches directed against Ab including
the extensively studied b-secretase (BACE1) inhibition. We used an
APP-transgenicmousemodel to test chronic BACE-inhibitor NB-360
treatment for effects on microhemorrhages. For these studies,
APP23 mice have been chosen as animal model because they
develop extensive CAA and microhemorrhages during aging
(Winkler et al., 2001). MRI during the treatment followed by
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microhemorrhages by BACE inhibition in contrast to Ab immuno-
therapy tested in parallel. T2*-weighted MRI revealed an age-
dependent increase of lesion volume in the control group.
Furthermore, a more profound enhancement of MRI lesion volume
after b1-antibody treatment was obvious. A 6.5-fold increase of the
lesion volume quantiﬁed byMRI in vivo could be observed in APP23
females treated with the b1 antibody compared with a 3-fold in-
crease in the control group, the latter showing the aging effect in
the APP23 mice. Lesion numbers measured by T2*-weighted MRI
increased also during aging as reported previously (Beckmann et al.,
2011). However, we did not observe an increase of T2*-weighted
MRI lesion numbers in the b1-treatment group compared with
control mice. The sensitivity of MRI in combination with the
intravenous administration of iron oxide nanoparticles (super-
paramagnetic iron oxide [SPIO]) to noninvasively monitor the
development of vascular pathology and its possible enhancement
by Ab immunotherapy in transgenic mice modeling AD has been
shown earlier (Beckmann et al., 2011). Consistent with the ability of
SPIO nanoparticles to label macrophages (Beckmann et al., 2009),
histology of sites displaying signal attenuation in the MRI brain
images demonstrated the presence of iron-containingmacrophages
in the vicinity of CAA-affected blood vessels (Beckmann et al., 2011).
In that work, treatment with the b1 antibody after a similar pro-
tocol as adopted here (including the age of the animals), led to an
increase of sites displaying signal attenuation in the brains of APP23
mice. This result suggests an increase in sensitivity for detecting
vascular abnormalities by SPIO administration, as both the presence
of iron-loaded macrophages and microhemorrhages might have
contributed to the signal attenuation sites, in contrast to the present
study, in which only microhemorrhages were detected by MRI.
Histopathological analyses of microhemorrhages in the brain
with Perls’ Prussian blue staining after 3months treatment revealed
several weak microbleeds. In standard histopathological evalua-
tions, 3 brain sections fromdifferent parts of thebrainwereanalyzed
by blinded grading by a pathologist. Grading of the microbleeds
revealed no signiﬁcant differences between the treatment groups,
only a weak trend could be observed. It was noted that most of the
MRI-detected lesions were concentrated in the anterior part of the
brain, in the cortex, and thalamus, and no lesions were detected in
the posterior part. Thus, MRI may help to direct the focus of ex vivo
histopathological analyses to the respective areawhichwill result in
much more reﬁned, robust, and representative outcomes in stan-
dard histopathological evaluations. Digital image quantiﬁcation
reﬁned the histopathological analyses by counting Perls’ positive
staining. This quantitative image analysis showed that hemosiderin
cluster analysis could offer an important advantage to reveal
microhemorrhage events in the brain. By this method, we could
observe a slight but not statistically signiﬁcant increase of Perls’
positive cluster numbers in b1-antibody treated animals compared
with controls, furthermore conﬁrming the only subtle and sparse
appearance of microhemorrhages and the strong advantage of lon-
gitudinal and noninvasive MRI. This is even further substantiated
when combining histological and MRI images. Three-dimensionsal
reconstruction and rendering of lesions revealed that MRI detects
small Perls’ positive areaswith sufﬁcient extent along the z-axis that
may be missed in the histological analysis of a few sections.
How microhemorrhages are induced by antibodies is still under
debate; induction of inﬂammatory responses (Eng et al., 2004;
Ferrer et al., 2004; Nicoll et al., 2003), remodelling of the vascula-
ture after fast removal of amyloid deposits from the parenchyma,
and further transient excessive Ab deposition in the vasculature
(Boche et al., 2008) have been shown to be important factors.
Nevertheless, in contrast to the b1 antibody, BACE-inhibitor NB-360
treatment did not further increase any CAA-relatedmicrohemmorhages. In the present study, we used NB-360 at a dose
of 30 mmol/kg/d that ensured a substantial reduction of Ab in the
brain. At this dose, brain Ab40 and Ab42 were signiﬁcantly reduced
by 28% and 25%, respectively, compared with vehicle, but not below
baseline. In agreement to previous data, b1 treatment signiﬁcantly
reduced Ab42 by 18% but not Ab40 in the brain (Pfeifer et al., 2002).
Taken together, volumetric assessment by MRI enables in vivo
monitoring of cerebral microhemorrhages in animal studies and
reduced and reﬁned the labor intensive work of histopathological
characterization with better outcome. An additional advantage of
the technique is its translational character, which is particularly
relevant in the context of drug development. Furthermore, this
study showed that BACE-inhibitor treatment did not increase the
number or severity of microhemorrhage events.Disclosure statement
During the planning and execution of the experiments all au-
thors were employees of Novartis Pharma AG, Basel, Switzerland.
The study has been performed with internal funding of Novartis
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